Journal of Clinical Endocrinology & Metabolism, Vol 52, 156-158, Copyright © 1981 by Endocrine Society

ARTICLES

Elevations in unbound serum estradiol as a possible mechanism for inappropriate gonadotropin secretion in women with PCO

RA Lobo, L Granger, U Goebelsmann and DR Mishell Jr

Twenty-three women considered to have polycystic ovarian disease (PCO) were studied in an effort to better understand the mechanism of inappropriate secretion (IGS) which is so characteristic of these women. Criteria for PCO included oligomenorrhea, infertility, an obesity index (ponderal index, PI) < 12, and an LH:FSH ratio > 3. The mean +/- SE weight and PI for this group were 175 +/- 7.5 lbs. and 11.2 +/- 0.2 respectively. Weight was not correlated with steroid levels in PCO or control women. The mean (+/- SE) of serum androgen concentrations (DHEA-S: 2.9 +/- 0.5 micrograms/ml; androstenedione: 2.6 +/- 0.3 ng/ml; and testosterone: 47 +/- 5 ng%) were all significantly higher than those in control women (p < .05). Total serum estradiol (E2) was comparable to those of controls in the follicular phase, while estrone (E1): E2 ratios averaged 2:1. Serum sex hormone binding globulin-binding capacity (SHBG-BC) averaged 56.8 +/- 4.2 nM which was significantly lower than that of controls (p < .05). The percent unbound E2 was significantly elevated in PCO (62% vs 37%). The mass of unbound E2 was also significantly higher in PCO women (40 +/- 3 pg/ml) than in controls (17 +/- 2 pg/ml) (p < .005). Serum LH:FSH ratios had a positive correlation with the relative and absolute concentration of unbound E2. In control women, unbound E2 correlated significantly with LH levels. This suggests that IGS characteristically found in PCO patients and exemplified by elevated LH;FSH ratios, is the result of the feedback response to elevated levels of unbound (i.e., biologically active) E2.

This article has been cited by other articles:

				I. E. Messinis Ovarian feedback, mechanism of action and possible clinical implications Hum. Reprod. Update, September 1, 2006; 12(5): 557 - 571. [Abstract] [Full Text] [PDF]

				R. T Chatterton Jr, E. T Mateo, N. Hou, A. W Rademaker, S. Acharya, V C. Jordan, and M. Morrow Characteristics of salivary profiles of oestradiol and progesterone in premenopausal women J. Endocrinol., July 1, 2005; 186(1): 77 - 84. [Abstract] [Full Text] [PDF]

				P. Gabant, L. Forrester, J. Nichols, T. Van Reeth, C. De Mees, B. Pajack, A. Watt, J. Smitz, H. Alexandre, C. Szpirer, et al. Alpha-fetoprotein, the major fetal serum protein, is not essential for embryonic development but is required for female fertility PNAS, October 1, 2002; 99(20): 12865 - 12870. [Abstract] [Full Text] [PDF]

				G. E. Hale, C. L. Hughes, and J. M. Cline Endometrial Cancer: Hormonal Factors, the Perimenopausal ""Window of Risk,"" and Isoflavones J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 3 - 15. [Abstract] [Full Text] [PDF]

				S. Kirchengast and J. Huber Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome Hum. Reprod., June 1, 2001; 16(6): 1255 - 1260. [Abstract] [Full Text] [PDF]

				E. Carmina, F. Gonzalez, A. Vidali, F.Z. Stanczyk, M. Ferin, and R.A. Lobo The contributions of oestrogen and growth factors to increased adrenal androgen secretion in polycystic ovary syndrome Hum. Reprod., February 1, 1999; 14(2): 307 - 311. [Abstract] [Full Text] [PDF]

				T. M. Fiad, T. P. Smith, S. K. Cunningham, and T. J. McKenna Decline in Insulin-Like Growth Factor I Levels after Clomiphene Citrate Does Not Correct Hyperandrogenemia in Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2394 - 2398. [Abstract] [Full Text]

				A. E. Taylor, B. McCourt, K. A. Martin, E. J. Anderson, J. M. Adams, D. Schoenfeld, and J. E. Hall Determinants of Abnormal Gonadotropin Secretion in Clinically Defined Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2248 - 2256. [Abstract] [Full Text] [PDF]